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ABSTRACT 26 
Background: Standardised alcohol craving scales are rarely used outside of research 27 
environments despite recognised clinical utility. Scale length is a key barrier to more 28 
widespread application. A brief measure of alcohol craving is needed to improve research and 29 
treatment of Alcohol Use Disorders (AUDs). Grounded in the Elaborated Intrusion Theory of 30 
Desire, the Alcohol Craving Experience (ACE) questionnaire comprises two 11-item self-31 
report scales which assess past-week frequency and maximum strength of alcohol craving. 32 
This study aimed to create a brief version of the ACE while maintaining psychometric 33 
integrity and clinical utility.  34 
Methods: Patients attending a university hospital alcohol and drug out-patient service 35 
for treatment of AUD completed the ACE as part of a questionnaire battery. Three patient 36 
samples were utilised: 519 patients with pre-treatment and outcome data; 228 patients with 37 
pre-treatment data; and 66 patients who completed the ACE at treatment sessions one and 38 
two.  39 
Results: The Frequency scale of the ACE possessed greater clinical utility and 40 
predictive validity than the Strength scale. Revision of the Frequency measure produced a 5-41 
item ‘Mini Alcohol Craving Experience’ (MACE) questionnaire. Satisfactory validity 42 
(construct, predictive, concurrent, convergent, and incremental) and reliability (internal and 43 
test-retest) was maintained. A one standard deviation increase in pre-treatment MACE score 44 
was associated with a 54 percent increase in the odds of patient lapse or dropout.  45 
Conclusions: The MACE provides a brief, theoretically and psychometrically robust 46 
measure of alcohol craving suitable for use with AUD populations in time-limited clinical 47 
and research settings. 48 
Keywords: Alcohol Use Disorder, Craving, Urge, Measurement, Scale development49 
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INTRODUCTION 50 
Craving is a robust marker of substance dependence severity and is implicated in 51 
treatment relapse (Flannery et al. 2003; Law et al. 2016; Yoshimura et al. 2016). The 52 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) recently 53 
included ‘craving, or a strong desire or urge to use a substance’ as a diagnostic criterion for 54 
Substance Use Disorders (American Psychiatric Association, 2013). Craving was defined as a 55 
strong desire to consume a substance that makes it difficult to think of anything else 56 
(American Psychiatric Association, 2013; Hasin et al. 2013). Craving interventions feature 57 
prominently in psychological treatments, and  pharmacotherapies have been developed to 58 
target specific craving neuromechanisms (Addolorato et al. 2005; Haass-Koffler et al. 2014).  59 
After decades of experimental, clinical, and epidemiological research, accurate measurement 60 
of substance craving remains a research priority (Tiffany and Wray 2012; Kavanagh et al. 61 
2013). Historically, craving has been measured by conceptually weak and often 62 
unstandardised methods, limiting generalisability and clinical utility (Sayette et al. 2000; 63 
Pavlick et al. 2009; Kavanagh et al. 2013). Some standardised scales have been introduced, 64 
although uptake within clinical settings has been poor (Pavlick et al. 2009; Tiffany and Wray 65 
2012).  66 
A national survey of U.S. addiction services found 99% considered craving in 67 
treatment planning, yet only 5% employed standardised self-report craving measures (Pavlick 68 
et al. 2009). The majority opted for single-item or non-standard open ended questions, despite 69 
well documented limitations to the reliability of these approaches (Cortina 1993; Hruschka et 70 
al. 2004). This may reflect the psychometric and theoretical weaknesses in self-report craving 71 
scales (Sayette et al. 2000; Kavanagh et al. 2013) and time burden imposed by scale 72 
administration and analysis in busy clinical environments. Alcohol Use Disorders (AUDs) are 73 
among the most prevalent Substance Use Disorders, placing a substantial burden upon global 74 
Page 4 of 32 
 
 
mortality and disease (Connor and Hall 2015; Gowing et al. 2015; Connor et al. 2016). A 75 
brief, psychometrically sound measure of alcohol craving is needed to improve assessment, 76 
diagnosis, and treatment of AUDs. 77 
Measures vary considerably in their definition of craving. In a recent review of 78 
alcohol craving scales, based on 47 papers published between 1990 and 2012, we argued that 79 
the majority contain constructs extraneous to widely applied diagnostic definitions of craving 80 
(e.g. DSM-5, ICD-10; Kavanagh 2013). These often include items measuring allied 81 
constructs, such as expectancies, intentions, and refusal self-efficacy (Kavanagh et al. 2013). 82 
Though such constructs are important within models of substance use and craving, the 83 
presence of these allied phenomena may influence accurate diagnosis of AUD and bias 84 
conclusions drawn from subsequent research. For example, the inclusion of items assessing 85 
self-efficacy (Bandura 1977) may artificially inflate the predictive utility of a scale, as self-86 
efficacy about drinking control reliably predicts drinking behaviour (Connor et al. 2007). 87 
The presence of allied addiction constructs does not necessarily compromise the 88 
validity of a craving scale. If the outcomes are interpreted in the context of a prescribed 89 
definition or with regard to a theoretical model then construct validity may be maintained. 90 
However, craving scales infrequently report a definition to which they adhere and are often 91 
developed atheoretically (Flannery et al. 1999; Rojewski et al. 2015; McHugh et al. 2016). 92 
We developed the Alcohol Craving Experience (ACE) Questionnaire to be consistent with 93 
common definitions of craving while adhering to a specified theory (Statham et al. 2011). 94 
However, administration of the 22-item ACE is likely to be too time consuming for practical 95 
use. It is proposed that reduction of the ACE would result in a theoretically and 96 
psychometrically sound measure of craving which may be easily integrated in time-limited 97 
environments. 98 
 99 
Page 5 of 32 
 
 
Reflecting the Elaborated Intrusion (EI) Theory of Desire (Kavanagh et al. 2005; May 100 
et al. 2014b), the ACE measures three aspects of craving: the intensity of the drive to drink 101 
(Intensity), the presence of associated imagery (Imagery), and intrusiveness of desire 102 
cognitions (Intrusion; Statham et al. 2011). EI theory defines craving as an affectively laden 103 
cognitive event, where an object or activity and its associated pleasure or relief is in focal 104 
attention (Kavanagh et al. 2005). Consistent with neurobiological models of craving, 105 
addictive substances are believed to recruit the same physiological mechanisms that drive 106 
appetitive behaviours required for survival (Robinson and Berridge 1993). EI theory proposes 107 
that biological, environmental, and affective cues trigger intrusive desire-related cognitions 108 
which occupy attention and prompt elaboration. The subsequent elaboration process—in 109 
particular imagery—provides momentary pleasure or relief of physical and emotional 110 
discomfort (Connor et al. 2014). However, pleasure or relief from elaborative cognitions 111 
quickly dissipates. Instead, awareness is drawn to any emotional or physical deprivation and 112 
to potential actions to acquire the target. Further elaboration and intensification of the desire 113 
ensues, unless the target is acquired or attention is captured elsewhere.  114 
EI theory aligns with treatment approaches such as motivational enhancement, 115 
mindfulness, acceptance-based therapies, and retraining attentional biases (Witkiewitz et al. 116 
2013; May et al. 2014b; Witkiewitz et al. 2014). Recent research has directly employed EI 117 
theory in the development of promising new craving management strategies and novel 118 
treatment approaches  (Kemps and Tiggemann 2007; Knäuper et al. 2011; Kemps and 119 
Tiggemann 2013; Hsu et al. 2014; Skorka-Brown et al. 2014; Littel et al. 2016). These 120 
approaches employ non-substance imagery and sensory tasks designed to compete with 121 
craving-based imagery within the limited capacity of working memory. The information 122 
provided by the ACE may facilitate more detailed formulation, treatment planning, and 123 
monitoring of craving.   124 
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The ACE was originally developed in an AUD sample (Statham et al. 2011), to 125 
measure the frequency (ACE-F) and peak strength (ACE-S) of alcohol craving over the 126 
previous week. Exploratory and confirmatory factor analysis showed that the items in both 127 
forms of the ACE cluster into three distinct factors consistent with EI theory: Intensity, 128 
Imagery, and Intrusion of craving-related cognitions. The ACE has high internal reliability 129 
and significantly correlates with the Obsessive Compulsive Drinking Scale (OCDS), Alcohol 130 
Use Disorders Identification Test (AUDIT), as well as measures of psychological distress 131 
highly comorbid with AUDs. The ACE has further been demonstrated to discriminate non-132 
clinical from clinical samples (Statham et al. 2011). May and colleagues (2014) pooled 12 133 
studies using modified forms of the ACE to assess craving across a range of substances, 134 
including alcohol (May et al. 2014a). The original factor structure was replicated across all 135 
substances.  136 
The ACE provides a theoretically grounded, psychometrically robust measure, with 137 
strong rationale for more effectively targeting alcohol craving interventions, and has shown 138 
its value in research settings. For clinical settings, however, the full ACE is repetitive (with 139 
each item appearing in both the Strength and Frequency forms) and time consuming. A 140 
shorter version of the ACE is likely to result in higher uptake, especially where repeated 141 
administration is required. The aim of this study is to develop a short form of the ACE for use 142 
in treatment planning and outcome assessment without compromising its theoretical 143 
foundation or psychometric integrity.  144 
MATERIALS AND METHODS 145 
Participants 146 
Three samples of data were drawn from patients attending a metropolitan university 147 
hospital alcohol and drug out-patient service. The service comprises eight sessions of 148 
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Cognitive Behaviour Therapy (CBT) conducted over 12 weeks. Treatment may be 149 
supplemented by pharmacotherapy (naltrexone, acamprosate, or both). The assessment 150 
battery is completed in a separate consultation prior to the first treatment session and again at 151 
the completion of treatment. All patients were over 18 years of age and met DSM-IV 152 
(American Psychiatric Association 2000) criteria for alcohol dependence. Human ethics 153 
approval was obtained (2008/125, HREC/12/QPAH/022 HREC/14/QPAH/664) and 154 
participants provided informed written consent. Sample characteristics are presented in Table 155 
1.  156 
 157 
Scale Reduction Sample. This sample comprised 519 alcohol dependent patients 158 
(Table 1). All patients were over 18 years of age and met DSM-IV(American Psychiatric 159 
Association 2000) criteria for alcohol dependence. These data have been used previously in 160 
the original development of the ACE (Statham et al. 2011) and in examining craving as a 161 
mediator of change (Law et al. 2016), but have not been used to directly predict treatment 162 
outcome.  163 
 164 
Validation Sample. The validation sample comprised pre-treatment data from 228 165 
consecutively treated alcohol dependent patients (Table 1). These data were employed to 166 
assess the factor structure of the ACE scales and cross-sectional relationships between 167 
variables. 168 
 169 
Test-Retest (TRT) Sample. The ACE-F was administered to 66 patients at treatment 170 
sessions one and two, in-order to assess test-retest reliability of the ACE-F. Mean time 171 
between sessions was 8.40 days (SD = 2.86).  172 
 173 
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Insert Table 1 174 
 175 
 176 
Measures 177 
The Alcohol Craving Experience (ACE) questionnaire. The ACE comprises two 11-178 
item scales that assess the frequency (ACE-F) and peak strength (ACE-S) of desire-related 179 
cognitions over the previous week. Items load onto three classes of cognition, ‘Intensity’ 180 
(items 1-3), ‘Imagery’ (items 4-8), and ‘Intrusion’ (items 9-11). Participants respond via an 181 
11-point visual analogue scale with anchors 0 (not at all) and 10 (constantly/extremely). The 182 
ACE-F and ACE-S have good internal reliability and concurrent validity, and can 183 
discriminate between problem and non-problem drinkers (Statham et al. 2011).  184 
 185 
The Obsessive Compulsive Drinking Scale (OCDS). The OCDS is a 14-item self-186 
report measure intended to reflect drinking-related obsessive and compulsive craving and 187 
behaviour (Anton et al. 1995). The OCDS has received extensive research attention and is 188 
currently the most widely used measure of alcohol craving. The OCDS has acceptable test-189 
retest reliability, internal reliability, and concurrent validity (Anton et al. 1995; Kranzler et al. 190 
1999; Roberts et al. 1999). The OCDS cannot be considered a ‘pure’ measure of craving as 191 
extraneous constructs such as consumption, effort to resist drinking, functional interference 192 
and distress from drinking, as well as perceived control of drinking are all assessed within the 193 
scale. The first six items, comprising the Obsessions Subscale are most consistent with the 194 
clinical definitions of craving. OCDS-Obsessions is intended to assess drinking obsession 195 
related cognitions, for example, “How much of your time when you’re not drinking is 196 
occupied by ideas, thoughts, impulses, or images related to drinking?”. While less 197 
confounded than the full OCDS, OCDS-Obsessions does contain extraneous phenomena, 198 
assessing functional interference and distress caused by obsessive cognitions. OCDS-199 
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Obsessions has been demonstrated to improve prediction of drinking behaviour (Flannery et 200 
al. 2003) and likelihood of relapse post treatment (Soyka et al. 2010). As OCDS-Obsessions 201 
is a widely used measure of craving and considered among the better performing craving 202 
scales (Kavanagh et al. 2013) it was employed as a concurrent measure of alcohol craving.  203 
 204 
The Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 10-item, 205 
self-report measure assessing recent alcohol use, symptoms of alcohol dependence, and 206 
alcohol related problems (Saunders et al. 1993). The AUDIT has sound internal reliability, 207 
sensitivity and specificity, and discriminant validity (Saunders et al. 1993). Higher scores 208 
indicate increased risk of harmful or hazardous drinking. 209 
 210 
The Beck Depression Inventory - Second Edition (BDI-II). The BDI-II is a 21-item 211 
self-report measure assessing attitudes and behaviours symptomatic of depression (Beck et al. 212 
1996). The BDI-II is a well validated measure demonstrating strong test-retest and internal 213 
reliability, as well as good concurrent, content, discriminant, and construct validity (Beck et 214 
al. 1988; Beck et al. 1996).  215 
 216 
The State Anxiety Scale (S-Anxiety). The S-Anxiety Scale of the State Trait Anxiety 217 
Inventory (STAI) comprises 20 self-report items assessing the respondent’s current state of 218 
anxiety (Spielberger 1983). The S-Anxiety has acceptable internal and test-retest reliability, 219 
as well as content, discriminant, and construct validity (Spielberger 1983; Oei et al. 1990; 220 
Barnes et al. 2002).  221 
 222 
Procedure 223 
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Scale Reduction. To best maintain consistency of the measured construct, an initial 224 
step involved selection of a form of the ACE for further refinement (ACE-F or ACE-S). Each 225 
form was evaluated based on perceived clinical utility and predictive validity. Decisions 226 
guiding subsequent item reduction were informed by the following rationale: (a) to enhance 227 
construct validity, items with the greatest face validity and theoretical importance within EI 228 
theory were prioritised; (b) to maximise the sensitivity and clinical utility of a reduced scale, 229 
the most highly endorsed items were also prioritised for retention; (c) to enhance predictive 230 
validity, the capacity of items to discriminate between patients who lapsed or withdrew from 231 
treatment and those who were abstinent throughout treatment was also considered. Data 232 
analyses within this step utilised the Scale Reduction Sample. 233 
 234 
Scale Evaluation. Reduced models were further evaluated based on construct, 235 
predictive, concurrent, and convergent validity, as well as internal and test-retest reliability. 236 
Predictive validity of OCDS-Obsessions was also assessed for concurrent comparison. Data 237 
analysis within this step utilised the Validation and Test-Retest samples. 238 
 239 
Scale Selection. The shortest scale maintaining psychometric integrity would be 240 
selected as the final reduced version.  241 
 242 
Data Analysis 243 
Analyses were conducted in SPSS version 22. Confirmatory factor analyses (CFA) 244 
were conducted in R version 3.2.1 (R Core Team 2015), package extension lavaan .5-18  245 
(Rosseel 2012). As the distributions of all ACE item and scale scores were significantly 246 
negatively skewed, statistical procedures robust to non-normal distributions were utilised. 247 
CFA Models were compared using changes in χ2 /df ratios (smaller values indicating 248 
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improved fit; Carmines and McIver 1981), Comparative Fit Indices (CFI, values >.93 249 
indicating good fit; Hu and Bentler 1999) , Standardised Root Mean Square Residual 250 
(SRMR; Values <.07 indicating good fit; Hu and Bentler 1999), Root Mean Square Error of 251 
Approximation (RMSEA; values <.07 indicating good fit; Hu and Bentler 1999), and Akaike 252 
Information Criterion (AIC; smaller values indicating improved fit; Bozdogan 1987).  253 
 254 
RESULTS 255 
Scale Reduction 256 
Subscale-Selection. As the ACE-S asks the respondent to report on only the most 257 
severe episode of past week craving, it is influenced by contextual factors such as situational 258 
cues and novel stressors. Clinical value of this method is drawn from the isolation of a 259 
specific time-period where the patient may be most vulnerable to lapse. Alternatively, the 260 
ACE-F assesses the perceived frequency of craving symptoms over the past week, providing 261 
a more general overview of the patients craving experience. The ACE-F was subsequently 262 
identified as the preferred scale for reduction, based on its perceived benefit as a measure 263 
more sensitive to change in the patient’s typical craving experience.  264 
Using the Scale Reduction Sample, separate logistic regression analyses were 265 
employed to assess the capacity of pre-treatment ACE scale scores to predict the likelihood of 266 
treatment lapse relative to patients who were abstinent throughout treatment. Patients who 267 
discontinued treatment without record of lapse were conservatively included within the lapse 268 
group. All scale scores were standardised to facilitate the comparison of effects. AUDIT 269 
scores and medication status were included as covariates, but did not significantly improve 270 
upon the intercepts-only model (χ2 (2) = 0.26, p = .877, Nagelkerke R2 = .001; Table 2, 271 
Baseline Model). Inclusion of either the ACE-S (Δχ2 (1) = 18.71, Δp = <.001, Nagelkerke 272 
ΔR2 = .054, Table 2, Model 1) or ACE-F (Δχ2 (1) = 21.68, Δp = <.001, Nagelkerke ΔR2 = 273 
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.062, Table 2, Model 2) significantly improved the predictive power of the model. As Model 274 
2 appeared to explain more variance than Model 1, the ACE-F was added to Model 1 in an 275 
additional step to examine if it would account for significantly more variance than the ACE-276 
S. The addition of the ACE-F to Model 1, saw the ACE-F become the dominant predictor 277 
within the model, though predictive power was not significantly improved (Δχ2 (1) = 3.63, Δp 278 
= .057, Nagelkerke ΔR2 = .011, Table 2, Model 3). The ACE-F was subsequently selected for 279 
further refinement. 280 
 281 
Insert Table 2 282 
 283 
Item Importance. Prior to item reduction, the structure and items central to the 284 
theoretical foundation of the scale were considered. At least one item from each sub-scale 285 
was retained to represent each factor. Items 3 and 9 (Table 3) were prioritized for retention 286 
due to high semantic consistency to the Intensity and Intrusion factors respectively. Multiple 287 
items of the Imagery factor would be retained to capture potential individual differences in 288 
the most prevalent imagery modalities involved in alcohol craving.  289 
 290 
Feature Prevalence. Medians and interquartile ranges for all ACE-F items are 291 
presented in Table S1 within the online supplementary material. While all items had an 292 
interquartile range of at least 4 on the 11-point scale, most also received a large proportion of 293 
‘not at all’ responses. To identify which items were most representative of common craving 294 
symptoms among patients with AUD, the endorsement rates (ERs; proportion of non-zero 295 
responses to each item) were also calculated. McNemar’s χ2 was utilised to identify 296 
significant differences between items in the prevalence of endorsement rates within each 297 
factor. Within the Intensity factor, the endorsement rate of Item 2 (80.2%) was significantly 298 
Page 13 of 32 
 
 
lower than Item 3 (86.1%, p < .001), while Items 1 (87.6%) and 3 could not be distinguished 299 
(p = .169). Comparisons of endorsement rates of items within the Imagery factor revealed all 300 
were significantly different (p < .001), with the exception of the most highly endorsed, items 301 
4 (80.9%) and 8 (80.1%, p = .716). Within the Intrusion factor, item 11 was the least 302 
endorsed factor (75.8%, p < .001) while items 9 (84.9%) and 10 (83.8%) could not be 303 
differentiated (p = .291).  304 
Separate Mann-Whitney U tests revealed that the mean rank of patients who lapsed or 305 
withdrew from treatment was significantly higher for every item than those who completed 306 
treatment abstinent (Table 3). Steiger’s Z revealed no significant differences in the size of the 307 
effects between items.  308 
 309 
Insert Table 3 310 
 311 
Item Reduction. To maximize sensitivity of the reduced craving measure items with 312 
the highest endorsement rates were given greater priority for retention to minimise the 313 
number of ‘not at all’ responses within the reduced scale. Based on feature prevalence and 314 
consistency with the overarching factors, items 3 and 9 were retained to represent the 315 
Intensity and Intrusion factors respectively. The three imagery items with the highest 316 
endorsement rates (4, 5, and 8) were retained to comprise the initial Imagery factor.  317 
A sequential logistic regression was employed to assess the capacity for the selected 318 
items to predict alcohol lapse in the Scale Reduction Sample. Addition of the items intended 319 
to comprise the reduced ACE (items: 3, 4, 5, 8, 9) to the Baseline Model (Table S2) 320 
significantly improved predictive power of the model (Δχ2 (5) = 21.49, Δp < .001, 321 
Nagelkerke ΔR2 = .061, Model 4, Table S2). To assess whether the model could be improved 322 
with the inclusion of additional ACE items, the remaining items were included using forward 323 
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entry. Sequential inclusion of items 1 (Δχ2 (1) = 7.61, Δp = .006, Nagelkerke ΔR2 = .023, 324 
Model 5, Table S2) and 10 (Δχ2 (1) = 9.84, Δp =.002, Nagelkerke ΔR2 = .027, Model 6, Table 325 
S2) would significantly improve the final model (χ2 (9) = 39.20, p < .001, Nagelkerke R2 = 326 
.111). 327 
 328 
Scale Evaluation 329 
Validity. To assess the construct validity of the initial five-item scale, the seven-item 330 
scale, and the complete ACE-F, confirmatory factor analyses were performed utilising the 331 
Validation Sample. Maximum likelihood estimation with robust standard errors and a 332 
Satorra-Bentler scaled test statistic were employed to reduce the effects of non-normality. 333 
Model fit statistics are presented in table 4, and parameter estimates are summarised in the 334 
supplementary material. For the 11 and 7 item scales, the three-factor solution provided a 335 
better fit to the data than a unifactorial model (Table 4). For the five item scale, both 336 
solutions showed comparable fit. The CFI, RMSEA, SRMR, and AIC fit statistics all 337 
improved through reduction. No covariance between error terms was specified in any of the 338 
models. These results support previous studies validating the three-factor structure of the 339 
ACE (Statham et al. 2011; May et al. 2014a), though when reduced to a five-item scale, it 340 
could equally reflect a global construct of craving within a single factor (Figure 1).  341 
 342 
Insert Table 4 343 
Insert Figure 1 344 
 345 
Data from the Validation Sample indicated that all scales had significant (p < 0.001) 346 
large positive correlations with OCDS-Obsessions, indicating an acceptable level of 347 
concurrent validity (r = 0.60 to 0.58). Convergent validity was demonstrated by significant (p 348 
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< 0.01) small to moderate positive correlations with the AUDIT (r = 0.22 to 0.20) and 349 
significant (p < 0.001) moderate correlations with measures of anxiety (S-Anxiety: r = 0.40 350 
to 0.38) and depression (BDI: r = 0.39 to 0.38). The strength of the correlations did not 351 
significantly differ between the three ACE versions (Steiger’s Z, p <.05), indicating that 352 
convergent and concurrent validity of the ACE was not significantly affected by scale 353 
reduction.  354 
Utilising the Scale Reduction Sample predictive validity of the scales administered 355 
pre-treatment was assessed by logistic regressions with the outcomes ‘complete treatment 356 
abstinent’ and ‘lapsed or discontinued treatment’. When independently added to the Baseline 357 
Model, the five-item (Δχ2 (1) = 15.17, Δp < .001, Nagelkerke ΔR2 = .044, Model 7, Table 5), 358 
seven-item (Δχ2 (1) = 20.19, Δp < .001, Nagelkerke ΔR2 = .058, Model 8, Table 5), and 11-359 
item (Model 2, Table 2) scales all significantly improved predictive power of the model. 360 
Predictive power of OCDS-Obsessions was also assessed for concurrent comparison. 361 
Addition of OCDS-Obsessions significantly improved upon the Baseline Model (Δχ2 (1) = 362 
7.78, Δp =.005, Nagelkerke ΔR2 = .022, Model 9, Table 5). The incremental validity of each 363 
scale was assessed by systematically adding the weaker of two scales, based on Nagelkerke’s 364 
R2, to the Baseline Model, followed by the next strongest scale in step two. The 5-item ACE-365 
F was demonstrated to significantly improve upon the predictive power of OCDS-Obsessions 366 
(Δχ2 (1) = 7.35, Δp =.007, Nagelkerke ΔR2 = .044, Model 10, Table 5) and the 7-item scale 367 
significantly improved upon the 5-item (Δχ2 (1) = 15.43, Δp <.001, Nagelkerke ΔR2 = .088, 368 
Model 11, Table 5). The 11-item scale did not improve upon the seven-item scale (Δχ2 (1) = 369 
1.19, Δp = .173, Nagelkerke ΔR2 = .064, Model 12, Table 5).  370 
 371 
Insert Table 5 372 
 373 
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Reliability. Internal consistency was assessed using the Validation Sample. 374 
Cronbach’s Alpha was above .90 for all scales with only minor reductions in the reduced 375 
scales (α = 0.95 to 0.92). Test-Retest reliability utilised session one and two data from 66 376 
patients. Correlations between session one and session two ACE scores indicated that test-377 
retest reliability was acceptable across all scales (r = 0.731 to 0.725). Steiger’s Z revealed no 378 
significant changes in scale test-retest reliability following reduction. 379 
 380 
Scale Selection  381 
The procedures conducted indicate that the ACE-F may be reduced to as few as five 382 
items while maintaining theoretical and psychometric integrity. The five-item scale, termed 383 
the Mini Alcohol Craving Experience (MACE), was chosen as the most suitable short-form 384 
scale for assessment of craving in AUD populations.  385 
 386 
DISCUSSION 387 
In place of the two 11–item forms of the ACE, a brief five-item measure of craving 388 
was validated (MACE). The MACE maintained high construct, predictive, concurrent, and 389 
convergent validity.  High internal and test-retest reliability consistent with the ACE-F was 390 
also demonstrated. The MACE measures the frequency of past week craving including 391 
intense urges, imagery, and intrusiveness of craving related cognitions (Kavanagh et al. 392 
2005). The MACE is simple to administer and may be completed in less than 60 seconds, 393 
reducing time burden on respondents, health professionals, and researchers. 394 
In addition to its brevity, the MACE maintains several strengths uncommon among 395 
current craving instruments, including a strong theoretical model and absence of drinking 396 
constructs known to confound craving measurement (Sayette et al. 2000; Kavanagh et al. 397 
2013). By retaining the items most representative of the ACE factors, and monitoring the 398 
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resultant model fit, the MACE preserved the construct validity of the ACE. The MACE 399 
subsequently retains the capacity for unique insight into intensity and intrusiveness of patient 400 
craving, as well and key elements of craving based imagery. This information may inform 401 
case formulation and treatment planning.   402 
Predictive validity is infrequently examined in existing craving measures. Higher 403 
scores on the MACE were predictive of increased risk of lapse or dropout from treatment in 404 
this alcohol dependent sample. A one standard deviation increase in MACE score was 405 
associated with a 54% increase in the odds of lapse or discontinuation of treatment; relative 406 
to OCDS-Obsessions, where a one standard deviation score increase was associated with a 407 
10% increase in risk. The practical interpretation of this result is that for every one-point 408 
increase on the MACE pre-treatment (maximum score = 50), the odds of a patient completing 409 
treatment abstinent reduced by 3.1 percent. The MACE may therefore assist addiction 410 
professionals to better assess risk of relapse in their patients.  411 
Few craving measures assess test-retest reliability. The MACE deliberately measures 412 
past week frequency of craving, under the assumption that this will have greater stability and 413 
subsequently be a more reliable indicator of change than single time point assessments. The 414 
correlation of session one and two MACE scores was r = 0.73, and is interpreted as an 415 
acceptable degree of stability within the clinical context. Given the prominence of craving 416 
within clinical and research settings, a measure of craving sensitive to change over time is 417 
greatly needed. The MACE may enhance the validity of studies assessing the efficacy of 418 
craving interventions, and improve monitoring of patients’ treatment response in clinical 419 
settings.  420 
As this study was conducted in a hospital outpatient clinic, the samples provided 421 
optimal, clinically relevant data. However, the practical nature of the research design 422 
introduced some limitations. The samples predominantly comprised middle-aged men with 423 
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poor social or occupational functioning and moderate to severe alcohol dependence. Future 424 
studies should investigate the MACE in more diverse patient populations, as craving profiles 425 
may vary across problem severity, age, culture, social-occupational status. An additional 426 
limitation is that follow up data of patients who dropped out were not available, and were 427 
conservatively recorded as having lapsed. Assessment of test-retest reliability was also 428 
impaired by the treatment setting. An increased focus on drinking and attempts to change 429 
drinking behaviours is likely to have increased variance in patient craving from session one to 430 
two. While this is hypothesised to have led to the underestimation of the MACE’s stability 431 
future research should assess participants under stable conditions with tightly controlled time 432 
points. Further research is also needed to examine the performance of the MACE as a stand-433 
alone measure. As the MACE was only assessed as a sub-selection of the full ACE, the extent 434 
to which the variance of the retained items is influenced by the excluded items is unknown. 435 
Finally, while craving frequency presents ongoing challenges to the control of drinking, very 436 
intense peak levels also constitute significant risk. Utilising both frequency and strength 437 
forms of the ACE is recommended when time permits, as they offer a more comprehensive 438 
assessment of the patient’s experience of craving. The MACE and ACE scales, scoring 439 
instructions, and normative data are included in the online supplementary material. 440 
A final recommendation, which applies to the use of all craving measures, is that scale 441 
administrators, researchers and clinicians alike, carefully interpret scale scores in light of the 442 
definition and theory under which they are proposed. It is argued that unclear definitions, and 443 
the absence of theoretical models have impaired craving measurement to date, confounding 444 
the craving construct as it is widely understood (Tiffany and Wray 2012; Kavanagh et al. 445 
2013). Interpreting ACE scores in the context of the Elaborated Intrusion Theory of Desire 446 
(Kavanagh et al. 2005) will improve understanding of the proposed construct of craving and 447 
enhance its clinical utility. 448 
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The Mini Alcohol Craving Experience (MACE) reflects the key theoretical elements 449 
of the ACE, while maintaining the best performing items and preserving psychometric 450 
integrity. Key strengths of the MACE include excellent construct validity, predictive validity, 451 
and acceptable test-retest reliability. In conjunction with its brevity, these features make the 452 
MACE ideal for use with AUD populations in time limited clinical and research 453 
environments.  454 
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Table 1. Patient sample characteristics 595 
Sample characteristics Scale Reduction Sample Validation Sample TRT Sample 
  n = 519 n = 228 n = 66 
Mean Age, years (SD) 39.82 (11.59) 44.39 (10.82) 45.48 (10.03) 
Sex, female 171 (32.9%) 84 (36.8%) 22 (33.3) 
Married/De-facto 184 (35.5%%) 82 (36.0%) 25 (37.9%) 
Education  	 	
   Degree 70 (13.5%) 47 (20.5%) 17 (25.8%) 
   Diploma/Certificate 52 (10.0%) 16 (7.1%) 6 (9.1%) 
   Senior Secondary (Year 12) 157 (30.3%) 71 (31.1%) 22 (33.3%) 
   Junior Secondary (Year 10) 190 (36.6%) 82 (36.0%) 17 (25.8%) 
   Primary (Year 7) 33 (6.4%) 11 (4.8%) 4 (6.1%) 
Unemployed 103 (19.8%) 44 (19.3%) 15 (22.7%) 
Mean Alcohol (grams) per drinking day (SD) 147.07 (88.90) 169.80 (100.93) 196.12 (119.71) 
Median Baseline ACE-F (IQR) 39 (48.00) 42.00 (46.75) 43.50 (45.50) 
Mean Baseline AUDIT (SD) 27.25 (8.6) 29.38 (7.01) 27.47 (10.28) 
Mean Baseline OCDS-Obsessions (SD) 7.82 (4.47) 8.82 (4.36) 8.46 (4.76) 
Medication Prescribed* 315 (60.7%) 25 (11.0%) 10 (15.2%) 
*The Scale Reduction Sample records medication (naltrexone/acamprosate/both) if it is prescribed at any point during treatment. Medication is 596 
only counted in the Validation and TRT samples if it was taken in the week prior to assessment. As the Validation sample assessment occurred 597 
prior to commencement of behavioural treatment and TRT sample was assessed in Session 1, the majority of patients had not yet been prescribed 598 
pharmacotherapy.  599 
  600 
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Table 2. Summary of hierarchical logistic regression models assessing predictive validity of the ACE-F and ACE-S. 601 
 602 
  603 
    95% CI for Odds Ratio 
  β (SE) Lower Odds Ratio Upper 
Baseline Model     
  Constant 1.18*** (.13)  3.26  
  Medication 0.11 (.22) 0.73 1.12 1.71 
  AUDIT -0.00 (.11) 0.81 1.00 1.23 
Model 1     
  Constant 1.19*** (.14)  3.28  
  Medication 0.23 (.22) 0.81 1.26 1.96 
  AUDIT -0.04 (.11) 0.77 0.96 1.20 
  ACE-S 0.46*** (.11) 1.28 1.59 1.97 
Model 2     
  Constant 1.21*** (.14)  3.34  
  Medication 0.23 (.22) 0.81 1.26 1.95 
  AUDIT -0.05 (.11) 0.76 0.95 1.18 
  ACE-F 0.53*** (.12) 1.34 1.69 2.14 
Model 3     
  Constant 1.2*** (.14)  3.32  
  Medication 0.24 (.23) 1.27 1.27 1.98 
  AUDIT 0.05 (.11) 0.95 0.95 1.18 
  ACE-S 0.15 (.19) 1.17 1.17 1.70 
  ACE-F 0.39 (.20) 1.48 1.48 2.21 
Note: * p < .05, ** p < .01, *** p < .001,  
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 604 
Table 3. Mean rank comparison of abstinent patients and those who lapsed or dropped out of treatment across all ACE-F items scores.  605 
  Complete Abstinent 
Lapse or 
Dropout         
How often did these things happen over the last week? n Mean Rank n 
Mean 
Rank U Z p r 
1.  Did you want a drink? 118 196.24 398 276.96 16135.00 -5.19 <.001 -0.23 
2.  Did you think about needing a drink? 118 203.00 399 275.56 16933.00 -4.67 <.001 -0.20 
3.  Did you have an urge to drink? 118 203.95 399 275.28 17045.00 -4.58 <.001 -0.20 
4.  Did you picture alcohol or drinking? 118 215.42 399 271.89 18398.50 -3.64 <.001 -0.16 
5.  Did you imagine what it would taste like? 118 215.79 398 271.16 18442.50 -3.59 <.001 -0.16 
6.  Did you imagine what it would smell like? 118 217.61 399 271.24 18656.50 -3.54 <.001 -0.16 
7.  Did you imagine what it would feel like in your mouth or 
throat? 118 214.71 399 272.10 18315.00 -3.74 <.001 -0.16 
8.  Did you imagine how your body would feel if you had a 
drink? 118 223.04 398 269.01 19298.00 -2.96 0.003 -0.13 
9.  When you thought about alcohol over the last week, how 
often were the thoughts intrusive? 117 223.46 388 261.91 19241.50 -2.51 0.012 -0.11 
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	606 
Table 4. Robust fit indices for the 3-factor and unifactorial structures of the ACE scales (n = 228). 607 
 Scale χ2 (df) χ2 /df p CFI RMSEA SRMR AIC 
ACE-F 11  	 	 	 	 	
  Unifactorial 302.13 (44) 6.87 <.001 0.898 0.160 0.069 11236.7 
  3-Factor 158.92 (41) 3.88 <.001 0.954 0.112 0.056 11013.50 
ACE-F 7  	 	 	 	 	
  Unifactorial 78.91 (14) 5.64 <.001 0.955 0.143 0.040 7321.29 
  3-Factor 35.59 (11) 3.24 <.001 0.983 0.099 0.027 7265.35 
ACE-F 5  	 	 	 	 	
  Unifactorial 23.23 (5) 4.65 <.001 0.983 0.126 0.026 5197.70 
  3-Factor 23.47 (4) 5.87 <.001 0.982 0.146 0.026 5199.57 
	608 
  609 
10.  When you thought about alcohol over the last week, how 
often were you trying not to think about alcohol? 117 211.29 398 271.73 17818 -3.88 <.001 -0.17 
11.  Did you find it hard to think about anything else? 118 203.59 399 275.56 17003 -4.55 <.001 -0.20  
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Table 5. Summary of hierarchical logistic regression models assessing predictive validity of the reduced ACE-F Scales and OBS. 610 
	611 
    95% CI for Odds Ratio 
  β (SE) Lower Odds Ratio Upper 
Model 7     
  Constant 1.19*** (.14)  3.28  
  Medication 0.22 (.22) 0.8 1.25 1.93 
  AUDIT -0.04 (.11) 0.78 0.96 1.19 
  ACE-F-5 item 0.43*** (.12) 1.23 1.54 1.93 
Model 8     
  Constant 1.19*** (.14)  3.3  
  Medication 0.24 (.23) 0.82 1.27 1.98 
  AUDIT -0.04 (.11) 0.77 0.96 1.19 
  ACE-F-7 item 0.50*** (.12) 1.31 1.65 2.06 
Model 9     
  Constant 1.18*** (.14)  3.24  
  Medication 0.20 (.22) 0.79 1.23 1.9 
  AUDIT -0.07 (.11) 0.75 0.93 1.16 
  OBS 0.31** (.11) 1.09 1.37 1.71 
Model 10    
  Constant 1.19*** (1.4)  3.29  
  Medication 0.225 (.23) 0.8 1.25 1.95 
  AUDIT -0.06 (.11) 0.76 0.95 1.18 
  OBS 0.10 (.14) 0.84 1.1 1.44 
  ACE-F-5 item 0.37** (.14) 1.11 1.45 1.9 
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Model 11    
  Constant 1.22 (0.14)  3.38  
  Medication 0.26 (0.23) 0.83 1.29 2.02 
  AUDIT -0.03 (0.11) 0.77 0.97 1.21 
  ACE-F-5 item -2.21 (0.7) 0.03 0.11 0.43 
  ACE-F-7 item 2.67 (0.7) 3.65 14.39 56.77 
Model 12    
  Constant 1.22 (0.14)  3.37  
  Medication 0.21 (0.23) 0.8 1.24 1.93 
  AUDIT -0.06 (0.11) 0.76 0.94 1.17 
  ACE-F-7 item -0.40 (0.67) 0.18 0.67 2.48 
  ACE-F-11 item 0.93 (0.69) 0.66 2.55 9.82 
Note: * p < .05, ** p < .01, *** p < .001.  
	612 
	613 
	614 
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Figure 1. Unifactorial model of the 5-item ACE-F with standardised parameter. All paths are significant at p < .001. 616 
